Search details
1.
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
Blood
; 125(3): 516-24, 2015 Jan 15.
Article
in English
| MEDLINE | ID: mdl-25395418
2.
The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
Haematologica
; 106(8): 2242-2245, 2021 08 01.
Article
in English
| MEDLINE | ID: mdl-33626861
3.
Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
Cancer Res
; 79(9): 2339-2351, 2019 05 01.
Article
in English
| MEDLINE | ID: mdl-30862722
4.
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.
Bioconjug Chem
; 19(8): 1673-83, 2008 Aug.
Article
in English
| MEDLINE | ID: mdl-18637680
5.
Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
Nat Commun
; 8(1): 2127, 2017 12 19.
Article
in English
| MEDLINE | ID: mdl-29259179
6.
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
J Clin Invest
; 123(1): 335-9, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23221337
7.
PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Sci Signal
; 6(304): ra105, 2013 Dec 03.
Article
in English
| MEDLINE | ID: mdl-24300897
8.
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Sci Transl Med
; 3(76): 76ra27, 2011 Mar 30.
Article
in English
| MEDLINE | ID: mdl-21451123
9.
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
J Clin Invest
; 126(1): 404, 2016 Jan.
Article
in English
| MEDLINE | ID: mdl-26727232
Results
1 -
9
de 9
1
Next >
>>